CA2177570A1 - Procede pour traiter des troubles intestinaux - Google Patents

Procede pour traiter des troubles intestinaux

Info

Publication number
CA2177570A1
CA2177570A1 CA002177570A CA2177570A CA2177570A1 CA 2177570 A1 CA2177570 A1 CA 2177570A1 CA 002177570 A CA002177570 A CA 002177570A CA 2177570 A CA2177570 A CA 2177570A CA 2177570 A1 CA2177570 A1 CA 2177570A1
Authority
CA
Canada
Prior art keywords
tnf
agent
bile
production
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002177570A
Other languages
English (en)
Inventor
Graham Douglas Fischer Jackson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Unisearch Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPM8325A external-priority patent/AUPM832594A0/en
Application filed by Unisearch Ltd filed Critical Unisearch Ltd
Publication of CA2177570A1 publication Critical patent/CA2177570A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • AIDS & HIV (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne une méthode popur traiter ou prévenir chez un sujet les troubles intestinaux provoqués par un niveau élevé de facteur de nécrose des tumeurs (FNT) à l'intérieur de l'intestin. Cette méthode fait appel à l'administration au sujet d'un agent qui diminue l'action du FNT endoluminal ou limite la production et l'accumulation de FNT endoluminal. Cet agent peut être l'un des nombreux agents anti-FNT connus. Toutefois, il est préférable que l'agent soit un anticorps anti-FNT. On préfère également que l'agent soit administré directement dans l'intestin.
CA002177570A 1993-12-01 1994-12-01 Procede pour traiter des troubles intestinaux Abandoned CA2177570A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AUPM274093 1993-12-01
AUPM2740 1993-12-01
AUPM8325A AUPM832594A0 (en) 1994-09-21 1994-09-21 Bile tnf
AUPM8325 1994-09-21

Publications (1)

Publication Number Publication Date
CA2177570A1 true CA2177570A1 (fr) 1995-06-08

Family

ID=25644589

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002177570A Abandoned CA2177570A1 (fr) 1993-12-01 1994-12-01 Procede pour traiter des troubles intestinaux

Country Status (4)

Country Link
EP (1) EP0732938A4 (fr)
JP (1) JPH09505812A (fr)
CA (1) CA2177570A1 (fr)
WO (1) WO1995015179A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0585705B1 (fr) * 1992-08-28 1998-11-04 Bayer Corporation Utilisation d'anticorps monoclonaux anti-TNF pour le traitement des méningites bactériennes
DE69433817T2 (de) * 1993-09-24 2005-07-14 Advanced Immuni T, Inc. Lineare und cyklische peptide zur behandlung oder vorbeugung der crohn'schen krankheit und/oder der ulzerativen kolitis
DE69914932T2 (de) * 1998-10-20 2004-12-09 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Verwendung eines zytokine-produzierenden lactococcus stammes zur behandlung von kolitis
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
EP2583972B1 (fr) 2010-06-18 2018-04-18 Hayashibara Co., Ltd. Agent thérapeutique pour des maladies inflammatoires contenant de l'adénosine n1-oxyde en tant que principe actif

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8805792D0 (en) * 1988-03-11 1988-04-13 Celltech Ltd Medicaments
EP0355067A1 (fr) * 1988-08-19 1990-02-21 Celltech Limited Produits pharmaceutiques utiles dans le traitement des néoplasmes
GB8905400D0 (en) * 1989-03-09 1989-04-19 Jonker Margreet Medicaments
WO1992014455A1 (fr) * 1991-02-14 1992-09-03 The Rockefeller University PROCEDE POUR LIMITER LES CONCENTRATIONS ANORMALES DE TNF-α DANS LES TISSUS CHEZ L'HOMME
IL99120A0 (en) * 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
EP0732938A1 (fr) 1996-09-25
JPH09505812A (ja) 1997-06-10
EP0732938A4 (fr) 1997-03-19
WO1995015179A1 (fr) 1995-06-08

Similar Documents

Publication Publication Date Title
Patton et al. Development of partial tolerance to the gastrointestinal effects of high doses of recombinant tumor necrosis factor-alpha in rodents.
Alexander et al. A recombinant human receptor antagonist to interleukin 1 improves survival after lethal endotoxemia in mice.
Curfs et al. Immunological aspects of cerebral lesions in murine malaria.
RU2563179C2 (ru) Составы, содержащие антитела
Jeffers et al. A novel human fibroblast growth factor treats experimental intestinal inflammation
MacKay et al. Tumor necrosis factor activity in the circulation of horses given endotoxin
JP2010222364A (ja) 大腸炎処置のためのサイトカイン産生性ラクトコッカス株の使用
Mattner et al. Treatment with homodimeric interleukin-12 (IL-12) p40 protects mice from IL-12-dependent shock but not from tumor necrosis factor alpha-dependent shock
Michie et al. Sepsis, signals, and surgical sequelae (a hypothesis)
JP7386455B2 (ja) 乾癬の治療薬
WHERRY et al. Tumor necrosis factor and the therapeutic potential of anti-tumor necrosis factor antibodies
Lange et al. Immunodysfunction in acute-on-chronic liver failure
Remick et al. Pathophysiologic alterations induced by tumor necrosis factor
CA2177570A1 (fr) Procede pour traiter des troubles intestinaux
BRPI0208124B1 (pt) Uso de um anticorpo igy imunologicamente específico para a proteína paa associada à virulência de escherichia coli de ligação e eliminação (aeec)
JP2017514875A (ja) 失禁および他の括約筋不全障害を処置する方法
TWI828155B (zh) 吡咯并嘧啶類化合物的用途
US20010056067A1 (en) Methods for preventing and treating the insult-induced metabolic imbalance in humans and other animals
WO2021143912A1 (fr) Action thérapeutique d'un extrait de graisse acellulaire sur la stéatose hépatique et ses complications
US20030211103A1 (en) Use of primate IFN-gamma binding molecules
EP3218003A2 (fr) Escherichia coli pathogène atténué ou inactivé pour le traitement de cancer urogenital
CN113613644A (zh) 胃肠疾病及其症状的治疗
KR20050085167A (ko) Ｃｒｈ(코르티코트로핀 방출 호르몬)-ｕｃｎ(유로코르틴)시스템의 염증성 질병 치료에의 용도
JPH08295633A (ja) 高度蛋白異化状態の患者における合併症予防剤
May et al. Identification of tumour necrosis factor in the blood and peritoneal fluid of horses with colic

Legal Events

Date Code Title Description
FZDE Dead